StocksMediumUpdated•Originally published 13 November 2026•Updated 13 November 2026•
1 min read
Armata Pharmaceuticals Beats Q3 2026 Revenue and Earnings Estimates
Key Facts
1Armata Pharmaceuticals reported a quarterly loss of $0.24 per share, beating the Zacks Consensus Estimate of a $0.57 loss.
2The results show an improvement compared to a year ago when the company reported a loss of $0.42 per share.
Armata Pharmaceuticals' revenue exceeded analyst estimates for the third quarter of 2026, while the company reported a quarterly loss of $0.24 per share for the period ending September 2026. Zacks reported that these results outperformed analyst expectations of a $0.57 per share loss, showing improvement from the $0.42 per share loss recorded in the same quarter last year.
Armata Pharmaceuticals, trading under the ticker ARMP, closed at $3.89 on November 11, 2026. The stock traded between a low of $3.57 and a high of $3.89 during the session, following the company's success in narrowing net losses and beating revenue targets.